Jinxin Fertility sees slower decline in IVF treatment cycles

Jinxin Fertility Group Limited has reported a reduction in the rate of decline for overall IVF treatment cycles. The decrease in cycles slowed from -8.3% for the six months ended June 30, 2025, to -5.2% for the nine months ended September 30, 2025, compared to the same periods in 2024. This improvement is attributed to management initiatives and positive trends.

The group's flagship hospital in Chengdu saw its IVF treatment cycles catch up from a -6.1% decline in the first half of 2025 to a lesser -1.9% for the nine months ended September 30, 2025. In contrast, Shenzhen experienced slower improvements due to planned hospital relocation. Overseas operations, particularly in the United States, faced deferred cycles due to the postponement of California Senate Bill SB729, resulting in a -10.8% decline for the nine months ended September 30, 2025.

Overall, the Group recorded 21,035 IVF treatment cycles for the nine months ended September 30, 2025, down from 22,195 in the same period of 2024. The company has ceased operations in Laos, which is undergoing liquidation. Jinxin Fertility maintains confidence in the industry's long-term prospects, supported by its foundation and favorable national policies.